Oragenics (NYSEAMERICAN:OGEN) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Oragenics (NYSEAMERICAN:OGENFree Report) in a research note published on Tuesday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

Oragenics Stock Up 9.1 %

OGEN stock opened at $2.45 on Tuesday. Oragenics has a twelve month low of $2.10 and a twelve month high of $7.74. The business’s fifty day moving average price is $3.52.

Oragenics (NYSEAMERICAN:OGENGet Free Report) last announced its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter. The business had revenue of $0.01 million during the quarter.

Institutional Trading of Oragenics

A number of hedge funds have recently made changes to their positions in OGEN. Renaissance Technologies LLC lifted its position in shares of Oragenics by 116.5% in the second quarter. Renaissance Technologies LLC now owns 209,600 shares of the biotechnology company’s stock valued at $73,000 after buying an additional 112,800 shares during the last quarter. Millennium Management LLC increased its stake in shares of Oragenics by 591.6% during the second quarter. Millennium Management LLC now owns 128,733 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 110,119 shares during the period. Finally, State Street Corp increased its stake in shares of Oragenics by 8.1% during the first quarter. State Street Corp now owns 495,563 shares of the biotechnology company’s stock worth $171,000 after purchasing an additional 37,338 shares during the period. 2.07% of the stock is owned by institutional investors and hedge funds.

Oragenics Company Profile

(Get Free Report)

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.

Further Reading

Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.